Filter
99
Text search:
inactivated
vaccines
Featured
Recommendations
12
New Publications
26
Language
Document type
No document type
47
Guidelines
26
Studies & Reports
12
Fact sheets
6
Manuals
5
Training Material
1
Resource Platforms
1
Strategic & Response Plan
1
Countries / Regions
Global
6
Nigeria
4
Pakistan
4
Afghanistan
4
Philippines
3
Sierra Leone
2
Congo, Democratic Republic of
2
Ethiopia
2
Syria
2
Ukraine
2
Chile
2
Latin America and the Carribbean
2
Liberia
1
India
1
Somalia
1
Nepal
1
Germany
1
Kenya
1
South Africa
1
Papua New Guinea
1
South–East Asia Region
1
Africa
1
Authors & Publishers
Publication Years
Category
Countries
17
Clinical Guidelines
17
Women & Child Health
6
Public Health
3
Pharmacy & Technologies
3
Key Resources
1
Toolboxes
COVID-19
23
Polio
11
Rapid Response
6
TB
6
NTDs
6
Ebola & Marburg
5
HIV
4
Zika
3
Conflict
2
Refugee
2
2.0 Rapid Response
2
Cholera
1
Mental Health
1
Specific Hazards
1
Global Health Education
1
AMR
1
Planetary Health
1
Pharmacy
1
Health Financing Toolbox
1
NCDs
1
The new WHO recommendations for rabies immunization supersede the 2010 WHO position
on pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for rabies. These updated
recommendations are based on new evidence and directed by public health needs that are cost-,
dose- and time-sparing
...
The COVID-19 Vaccine (Whole Virion Inactivated) BBV152, COVAXIN® vaccine explainer includes key information on the vaccine specific requirements.
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th
...
Available in different languages
Polio vaccines: WHO position paper – June 2022
recommended
This position paper on polio vaccines replaces the 2016 WHO position paper, and summarizes recent developments in the field.
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat
...
Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed
to support decision making. A countrywide mass vaccination campaign with the
use of an ina
...
The position papers are intended for use by national public health officials and managers of immunization programmes. They may also be of interest to international funding agencies, vaccine advisory groups, vaccine manufacturers, health professionals, researchers, the scientific media and the genera
...
This global guidance provided the framework for over 100 countries to develop their NDVPs. This updated (second) version supersedes the previous version published in 16 November 2020. New information has been added on the following areas:
the COVID-19 Partners Platform;
the use of COVID
...
The technical note from the Global Task Force on Cholera Control (GTFCC) examines the risks and benefits of vaccinating pregnant women with WHO-prequalified oral cholera vaccines (OCVs) during mass vaccination campaigns. It highlights that three WHO
...
Despite high regional demand for vaccines valued at over US$ 1 billion annually, Africa’s vaccine industry provides only 0.1% of global supply. Vaccine inequity and hoarding at the start of the pandemic, which resulted in delays in obtaining COVID
...
The report presents current information (updated to September 2015) on candidate vaccines, therapies and medical devices for Ebola and gives an overview of completed and on-going trials.
Update 2021; Immunization, Vaccines and Biologicals
Interim guidance, 26 October 2021
This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021.
SAGE said moderately and severely immunocompromised persons should be offered an addition
...
When situations occur in which unwanted events are rightly or wrongly connected with vaccination, they may erode confidence in vaccines and the authorities delivering them. This document presents the scientific evidence behind WHO’s recommendation
...
In April 2020, Gavi and COVAX joined the Access to COVID-19 Tools Accelerator (ACT-A) to provide equitable global access to COVID-19 vaccines to tackle the pandemic. In June 2020, the Gavi COVAX Advance Market Commitment (AMC) was launched to financ
...
